

Advancing a leading autoimmune-focused company

March 2026



Forward-looking statements

Certain statements in this presentation, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, express or implied statements regarding future plans and prospects, including statements regarding the expectations or plans for discovery, preclinical studies, clinical trials and research and development programs, in particular with respect to claseprubart and DNTH212, and any developments or results in connection therewith, including the target product profile and administration of claseprubart and DNTH212; the anticipated timing of the initiation and results from those studies and trials; expectations regarding the clinical trial designs or indications; expectations regarding the time period over which the Company’s capital resources are expected to be sufficient to fund its anticipated operations; and expectations regarding market size, patient population size, and potential opportunities for complement therapies, in particular with respect to claseprubart and DNTH212. Claseprubart and DNTH212 are investigational agents that are not approved as therapies in any indication in any jurisdiction worldwide. The words “opportunity,” “potential,” “milestones,” “runway,” “will,” “anticipate,” “achieve,” “near-term,” “catalysts,” “pursue,” “pipeline,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,” “commit,” and similar expressions (including the negatives of these terms or variations of them) generally identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to, that preclinical testing of claseprubart and DNTH212 and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that the preliminary interim analysis based on a limited number of patients from the Part A open label portion of the claseprubart CAPTIVATE study in patients with chronic inflammatory demyelinating polyneuropathy may not be predictive of the results or success of the remaining patients treated in Part A or patients treated in Part B of the CAPTIVATE study, that the development of claseprubart or DNTH212 may take longer and/or cost more than planned, that the Company or its partner may be unable to successfully complete the clinical development of the Company’s compounds, that the Company or its partner may be delayed in initiating, enrolling or completing its planned clinical trials, and that the Company’s compounds may not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading “Risk Factors” included in the Company’s Annual Report on Form 10-K for the period ended December 31, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.

Nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Dianthus undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.



Advancing a leading autoimmune-focused company



Developing two autoimmune therapeutics with best-in-class, pipeline-in-a-product potential and targeting patient-friendly, infrequent S.C. self-administration

Claseprubart (aC1s mAb)

- Highly potent, ~8-week half-life, classical pathway (CP) inhibitor targeting active C1s
- Validated pipeline-in-a-product potential with positive Ph. 2 gMG results, early Interim Responder Analysis GO decision in Ph. 3 CIDP, and clinical PoC for CP inhibition in MMN
- Clinical and *in vitro* head-to-head data support potential for a more effective and convenient biologic with no boxed warning/REMS
- Targeting convenience of a single, self-administered S.C. 300mg/2mL autoinjector dosed every 2 or 4 weeks

DNTH212

(BDCA2 and BAFF/APRIL bifunctional fusion protein)

- Bifunctional BDCA2 and BAFF/APRIL inhibitor targeting two validated pathways
- Potential for enhanced efficacy from complementary mechanisms targeting innate and adaptive immune systems
- Demonstrated superior *in vitro* pDC depletion vs. litifilimab and superior serum Ig inhibition vs. povetacicept in NHPs
- Pipeline-in-a-product opportunity across multiple diseases with potential for Q4W or less frequent S.C. self-administration



Claseprubart 2026 milestones:

Ph. 3 gMG trial initiation (mid'26), Ph. 2 MMN top-line data (2H'26) and Ph. 3 CIDP Part B top-line guidance by YE'26

DNTH212 2026 milestones:

Update on indication prioritization (1H'26) and Ph. 1 healthy volunteer study top-line data (2H'26)




Strong financial position with cash of ~\$1.2B¹ and runway expected into 2030 to fund multiple near and long-term catalysts

1. Pro forma cash includes cash, cash equivalents and investments of ~\$514M as of 12/31/25 plus estimated net proceeds of ~\$676M from the March 2026 follow-on offering

Building on the promise of claseprubart to be a potential pipeline-in-a-product and best-in-class therapy in growing and underserved markets

Ph.2 MaGic Showed Rapid & Robust Improvements in gMG Q3'25

Claseprubart arms demonstrated rapid, sustained, and clinically meaningful improvements in MG-ADL score



MG-ADL improvements for participants treated with cl were rapid, sustained, clinically meaningful and statistically significant

CAPTIVATE Part A Early GO Decision in CIDP Q1'26


Announced early GO decision reached with less than 40 planned participants completing Part A in MMN

- CAPTIVATE Interim Analysis Objective**
 - Targeting response rate of 50% or greater (≥20 patients) in MMN (Part A) based on precedent set with aC1s inhibition
- GO Decision**
 - GO decision reached early after 20 confirmed responses in MMN (less than 40 planned participants completing Part A)
- Safety / Tolerability Update**
 - Independent DSMB reviewed the data to date and confirmed no related serious infections, no clinical symptoms or no related SAEs or discontinuations
- GO decision supports continued development of claseprubart at 300mg targeting a potentially best-in-disease biologic**

Ph. 2 MoMeNtum Top-line Data Anticipated 2H'26 2H'26





Phase 2 MoMeNtum top-line data in MMN anticipated 2H'26

A global, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and PK / PD of claseprubart administered S.C. following initial loading dose



Top-line data expected in 2H'26

Two clinical-stage candidates with best-in-class, pipeline-in-a-product potential

| | Claseprubart | | | DNTH212 |
|--|--|--|--|--|
| | gMG | CIDP | MMN | |
|  Indications | >100,000 U.S. patients | >40,000 U.S. patients | >10,000 U.S. patients | Update on Indication Prioritization in 1H'26 |
|  Market Insight | Multi-billion \$, growing market with opportunity for a best-in-disease, convenient therapy to expand first-line biologics use | Active C1s inhibition has shown robust efficacy in patients who were refractory, stable, and naïve to IVIg | Empasiprubart, a C2 inhibitor, demonstrated impressive efficacy in MMN, validating classical pathway inhibition | Targets both innate and adaptive immune systems, with superior <i>in vitro</i> pDC depletion vs. litifilimab and superior serum Ig inhibition vs. povetacicept in NHPs |
|  Our Opportunity | Ph. 2 data support potential for best-in-disease profile demonstrating rapid, robust, continuous symptom control with convenient, Q2W or Q4W S.C. dosing and a potentially differentiated safety profile | GO decision in CAPTIVATE Interim Responder Analysis reached early after 20 confirmed responders were achieved with less than 40 planned participants completing Part A | Demonstrated superiority vs. empasiprubart in head-to-head <i>in vitro</i> classical pathway potency experiment, with potential to be a best-in-disease therapeutic with limited competition | Validation of both BDCA2 and BAFF/APRIL targeted therapies support bifunctional approach, with potential for best-in-class efficacy |
|  Next Milestone | Ph. 3 Top-line Data in 2H'28 | Part B Top-line Guidance by YE'26 | Ph. 2 Data in 2H'26 | Ph. 1 HV Top-line Data in 2H'26 |

The left side of the slide features several overlapping, curved maroon shapes of varying sizes and orientations, creating a dynamic, abstract background element.

Claseprubart: Building a Best-in-Class Neuromuscular Franchise

Pursuing the power of consistent control...with one-click!

claseprubart



CONFIDENCE



Aim for Potent, Rapid,
Consistent Efficacy

Potential for
Best-in-Class Efficacy

Broad Potential in
Autoimmune Diseases

CLASSICAL



Upstream Inhibition Prevents
Pro-inflammatory C3a/C3b

Potential to Preserve
Immune Function

Targeting No Boxed
Warning or REMS

CONVENIENCE




<10-Second
Autoinjector

One-Click
Every 2 or 4 Weeks

Self-Administered
At Home or On-the-Go

Targeting a best-in-class, first-line biologic treatment for neuromuscular diseases

Claseprubart has opportunity to compete as a potential 1L biologic in three large and growing US neuromuscular markets



Claseprubart has potential to capture meaningful market share across three synergistic multi-billion dollar markets




**Claseprubart:
Opportunity to be a Best-in-
Class, First-Line Biologic for
Generalized Myasthenia Gravis**

Ultomiris is the leading blockbuster complement inhibitor, with continued growth driven by first-line biologic use in gMG

C5 Inhibitors (Ultomiris & Soliris) Global Sales (\$M)

~1/3 of sales in gMG¹; sales growth driven by U.S. biologic naïve gMG patients²



Ultomiris sales grew 15% in Q4'25... “driven by patient demand across indications, including the competitive gMG and PNH markets. In 2026, we expect Ultomiris to continue to grow, driven primarily by neurology indication, including new-to-brand patients and those switching from Soliris, as well as further market expansions. **We indicated peak year sales for Ultomiris to be above \$5 billion**, with contribution from both existing and new indications...”

Q4 2025 financial results transcript



“Currently, **less than 20% of (gMG) patients are on branded treatments, and we expect this to increase to approximately 50% in the next 3 years**. Additionally, **self-administered** medicine represent only a small part of this market today, and we expect this **segment to grow substantially.**”

Q2 2025 financial results transcript

Soliris & Ultomiris 2021 sales account for 1/1 – 6/30 & 7/21 – 12/31. Evaluate Pharma
Soliris / Ultomiris are approved in gMG, aHUS, NMOSD and PNH
1. Wall Street research estimate; 2. Astra Zeneca Q4 2024 results

The US gMG market has significant potential to expand as <20% of AChR+ patients¹ are treated with biologics

Significant opportunity for a highly differentiated, more patient-friendly biologic to expand use of biologics in gMG



Note: Positioning of claseprubart's target profile is illustrative. 1. Komodo claims data accessed 2013-2025, adjusted to account for 70% capture of real-world patient counts; AChR+ 85% of gMG. 2. Based on Dianthus market research and estimates. 3. 2025 US financial reports on gMG drugs. Soliris/Ultomiris adjusted for relative size of MG based on claims. Vyvgart adjusted for estimated CIDP sales. 4. Based on EvaluatePharma (Jan '26) and Dianthus market research and estimates. Assumes average biologic net price per patient of ~\$400,000 per year. AstraZeneca 2024 Investor Day estimated >36,000 AChR+ treated patients in future state. AstraZeneca Q2'25 earnings transcript expected 50% of gMG patients to be on branded treatments by 2028.

Survey of US Neurologists confirms significant opportunity for differentiated biologic in gMG market

Claseprubart aims to address the significant unmet needs in the gMG market



Total Neurologists 81

Neuromuscular specialists 67%

Generalists 33%

Academic 40%

Community based 60%



Sample Demographics

~17 years in active clinical practice (post-residency), on average

~93% of professional time spent providing direct patient care, on average

~40 gMG patients seen in the past 12 months, on average

~81%

of Neurologists believe patients would benefit from treatment options with **greater durability of symptom relief**

~78%

of Neurologists believe patients would benefit **from a more convenient treatment option**



~67%

of Neurologists would start more patients on a complement inhibitor if they **do not have a boxed warning or REMS requirement**

~72%

of Neurologists **prefer low-volume autoinjector** over high-volume prefilled syringe **due to ease of use & faster injection (i.e. <10 seconds)**



**MaGic Ph. 2 Results Support a
Potentially Best-in-Class
Treatment for gMG**

MaGic Ph. 2 top-line results support a potentially best-in-class treatment for gMG



Efficacy Endpoints

Strong results support claseprubart potential as a best-in-class complement inhibitor

- Rapid, sustained, statistically significant symptom improvements as measured by MG-ADL, QMG, MSE, MGC, MG-QoL-15r



Safety Endpoints

Generally well tolerated, with a potentially differentiated safety profile

- No encapsulated bacterial infections
- No symptoms indicative of autoimmune activation or DIL
- Supports no Boxed Warning or REMS



Optimal Dose

Comparable efficacy & safety across both 300mg/2mL and 600mg/4mL doses

- Target dose of 300mg/2mL Q2W will be in Ph. 3 study
- Supports convenient, infrequent, self-administration with same autoinjector as Dupixent

MaGic Ph. 2 results support a profile with the potential to displace C5 complement inhibitors and compete effectively with FcRns as first-line biologic treatment in growing MG market

Autoinjector for claseprubart administration is anticipated to be SHL Medical's Molly technology, patented or patent pending in the US, China, India, Japan, Korea, Taiwan and at the European Patent Office.

C5 efficacy data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations.

Drug-Induced Lupus (DIL) is an autoimmune syndrome triggered by specific medications, such as statins, TNF-alpha inhibitors, and ACE inhibitors/beta-blockers. A key distinguishing feature of DIL is its reversibility, as symptoms typically resolve once the offending medication is withdrawn.

MaGic is a global Ph. 2 trial in AChR+ gMG patients


A global, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and PK / PD of claseprubart administered S.C. following initial loading dose

Highlights

- **Design:** ~60 male and female subjects randomized to receive either claseprubart or placebo for 13 weeks
- **Inclusion:** ≥18 years old with AChR antibody + gMG
- **Dosing:** 15 or 20mg/kg I.V. Loading Dose followed by 300mg/2mL or 600mg/4mL S.C. Q2W starting Day 7

Endpoints

- **Primary:** Safety
- **Secondary / Exploratory:** Efficacy (MG-ADL, QMG, MSE, MGC, MG-QoL-15r)



MAGIC


Trial enrollment exceeded target, with 65 participants enrolled

Participant baseline characteristics were generally well balanced across arms

| AChR+ gMG participants | Placebo (N=22) | Claseprubart 300mg/2mL Q2W (N=21) | Claseprubart 600mg/4mL Q2W (N=22) |
|--|-------------------|---|---|
| Age, mean (SD), years | 52.2 (16.5) | 57.1 (13.7) | 55.3 (12.0) |
| Male, n (%) | 13 (59%) | 14 (67%) | 10 (45%) |
| Weight, mean (SD), pounds | 195.0 (48.0) | 192.5 (35.5) | 179.0 (35.4) |
| Duration of disease, median (range), years | 7.7 (0.4 – 21.2) | 3.0 (0.5 – 22.1) | 7.6 (1.0 – 37.3) |
| MG-ADL score at baseline, mean (SD) | 8.5 (2.9) | 8.2 (2.2) | 8.4 (2.6) |
| QMG score at baseline, mean (SD) | 14.2 (5.8) | 12.2 (2.7) | 12.2 (3.6) |
| MG Composite score at baseline, mean (SD) | 15.0 (7.8) | 16.3 (4.5) | 16.0 (5.3) |
| MG-QoL-15r score at baseline, mean (SD) | 14.3 (7.0) | 15.4 (6.6) | 14.9 (5.9) |
| MGFA class at screening, n (%) | | | |
| II | 7 (32%) | 11 (52%) | 12 (55%) |
| III | 12 (55%) | 10 (48%) | 9 (41%) |
| IVa | 3 (14%) | 0 (0%) | 1 (5%) |
| Prior thymectomy, n (%) | 8 (36%) | 6 (29%) | 7 (32%) |
| Baseline corticosteroid use, n (%) | 19 (86%) | 17 (81%) | 20 (91%) |
| Number of ISTs at baseline, n (%) | | | |
| 1 | 11 (50%) | 10 (48%) | 12 (55%) |
| >1 | 11 (50%) | 11 (52%) | 10 (45%) |
| FcRn use in prior 24 months, n (%) | 0 (0%) | 1 (5%) | 0 (0%) |
| Prior complement use, n (%) | 0 (0%) | 0 (0%) | 0 (0%) |

Statistically significant improvement in MG-ADL score for both claseprubart arms vs. placebo at Week 13

Mean Change in MG-ADL Score from Baseline at Week 13




| P-value | 300mg/2mL | 600mg/4mL |
|-----------|------------|------------|
| One-sided | P=0.0113* | P=0.0006* |
| Two-sided | P=0.0227** | P=0.0013** |

Statistically significant and clinically meaningful reductions in MG-ADL across both treatment arms

The change from baseline in MG-ADL was analyzed using a mixed effect model for repeated measures (MMRM) with treatment group, visit, treatment by visit interaction, stratification factors, and baseline measure included.
 *One-sided p-values are presented for comparisons of claseprubart vs placebo, with any p-value below 0.1 considered nominally statistically significant.
 **Two-sided p-values are presented for comparisons of claseprubart vs placebo, with any p-value below 0.05 considered nominally statistically significant.

Statistically significant improvement in QMG score for both claseprubart arms vs. placebo at Week 13

Mean Change in QMG Score from Baseline at Week 13




| P-value | 300mg/2mL | 600mg/4mL |
|-----------|------------|------------|
| One-sided | P=0.0144* | P=0.0111* |
| Two-sided | P=0.0288** | P=0.0222** |

Statistically significant and clinically meaningful reductions in QMG across both treatment arms

The change from baseline in QMG was analyzed using a mixed effect model for repeated measures (MMRM) with treatment group, visit, treatment by visit interaction, stratification factors, and baseline measure included.
 *One-sided p-values are presented for comparisons of claseprubart vs placebo, with any p-value below 0.1 considered nominally statistically significant.
 **Two-sided p-values are presented for comparisons of claseprubart vs placebo, with any p-value below 0.05 considered nominally statistically significant.

Claseprubart arms demonstrated rapid, sustained, and clinically meaningful improvements in MG-ADL score




MG-ADL improvements for participants treated with claseprubart were rapid, sustained, clinically meaningful and statistically significant as early as Week 1

The change from baseline in MG-ADL was analyzed using a mixed effect model for repeated measures (MMRM) with treatment group, visit, treatment by visit interaction, stratification factors, and baseline measure included. Bars represent standard error of the mean.

*One-sided p-values are presented for comparisons of claseprubart vs placebo, with any p-value below 0.1 considered nominally statistically significant.

Claseprubart arms demonstrated rapid, sustained, and clinically meaningful improvements in QMG score





QMG improvements for participants treated with claseprubart were rapid, sustained, clinically meaningful and statistically significant as early as Week 1

The change from baseline in QMG was analyzed using a mixed effect model for repeated measures (MMRM) with treatment group, visit, treatment by visit interaction, stratification factors, and baseline measure included. Bars represent standard error of the mean.

*One-sided p-values are presented for comparisons of claseprubart vs placebo, with any p-value below 0.1 considered nominally statistically significant.

>60% of participants on claseprubart 300mg/2mL achieved ≥ 5 point improvement in MG-ADL



Improvement in MG-ADL Total Score



Participants across both treatment arms achieved robust improvements in MG-ADL at Week 13

>60% of participants on claseprubart 300mg/2mL achieved ≥ 5 point improvement in QMG


Improvement in QMG Total Score



Participants across both treatment arms achieved robust improvements in QMG at Week 13

37% of 300mg/2mL claseprubart-treated participants achieved Minimal Symptom Expression on MG-ADL at Week 13

Minimal Symptom Expression (MSE)
% of Participants Achieving MG-ADL Score of 0 or 1 at Week 13




MSE supports potential best-in-class profile


The proportion of participants who achieve MSE was analyzed using a logistic regression with terms for treatment group, stratification factors, and baseline MG-ADL included.
*One-sided p-values are presented for comparisons of claseprubart vs placebo, with any p-value below 0.1 considered nominally statistically significant.

Statistically significant improvement in MGC for both claseprubart arms vs. placebo at Week 13

Mean Change in MGC Score from Baseline at Week 13



Mean Change in MGC Summed Muscle Score from Baseline at Week 13 (post-hoc analysis)




The change from baseline in MGC and MGC Summed Muscle Score were separately analyzed using a mixed effect model for repeated measures (MMRM) with treatment group, visit, treatment by visit interaction, stratification factors, and baseline measure included.

*One-sided p-values are presented for comparisons of claseprubart vs placebo, with any p-value below 0.1 considered nominally statistically significant.

Statistically significant improvement in MG-QoL-15r score for 300mg/2mL vs. placebo at Week 13

Mean Change in MG-QoL-15r Score from Baseline at Week 13



The change from baseline in MG-QoL 15r was analyzed using a general linear model with treatment group, stratification factors, and baseline measure included.
*One-sided p-values are presented for comparisons of claseprubart vs placebo, with any p-value below 0.1 considered nominally statistically significant.


Across key efficacy measures, claseprubart demonstrated robust and clinically meaningful responses

| | Placebo | Claseprubart 300mg/2mL Q2W | | Claseprubart 600mg/4mL Q2W | |
|---|---------|----------------------------|---------------------|----------------------------|---------------------|
| | | Absolute | Placebo-adjusted | Absolute | Placebo-adjusted |
| MG-ADL mean change from baseline at Week 13 | -2.8 | -4.6 | -1.8 (P=0.0113)* | -5.4 | -2.6 (P=0.0006)* |
| QMG mean change from baseline at Week 13 | -2.0 | -4.4 | -2.4 (P=0.0144)* | -4.5 | -2.5 (P=0.0111)* |
| MSE at Week 13 | 14% | 37% | 23% (P=0.0550)* | 27% | 13% (P=0.1031) |
| MGC mean change from baseline at Week 13 | -3.1 | -8.7 | -5.6 (P=0.0008)* | -8.6 | -5.5 (P=0.0008)* |
| MG-QoL-15r mean change from baseline at Week 13 | -3.9 | -6.1 | -2.2 (P=0.0414)* | -5.4 | -1.5 (P=0.1122) |

Claseprubart 300mg/2mL Q2W treatment arm achieved statistical significance vs. placebo across all five key efficacy measures

*One-sided p-values are presented for comparisons of claseprubart vs placebo, with any p-value below 0.1 considered nominally statistically significant.

Claseprubart demonstrated statistically significant and clinically meaningful improvements in MG-ADL





Note: For illustrative purposes only. Efficacy data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted. Statistical treatment of missing data may vary across studies shown. Source: SOLIRIS (Ph3 REGAIN; 1200mg Q2W regimen; worst-rank ANCOVA). ULTOMIRIS (Ph3 CHAMPION-MG; weight-based Q8W regimen with maintenance doses 3000-3600mg; MMRM ANCOVA with no imputation of missing data). ZILBRYSQ (Ph3 RAISE; 0.3mg/kg QD regimen, MMRM ANCOVA with no data censorship).

Additional secondary efficacy measures support claseprubart potential as best-in-class complement inhibitor

QMG Score

Minimal Symptom Expression (MSE)




Note: For illustrative purposes only. Efficacy data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted. Statistical treatment of missing data may vary across studies shown. Source: ULTOMIRIS (Ph3 CHAMPION-MG; weight-based Q8W regimen with maintenance doses 3000-3600mg; MMRM ANCOVA with no imputation of missing data).

Claseprubart was generally well tolerated, with a favorable, potentially differentiated safety profile in Phase 2

| | Placebo (N=22) | Claseprubart 300mg/2mL Q2W (n=21) | Claseprubart 600mg/4mL Q2W (n=22) |
|---|-------------------|--------------------------------------|--------------------------------------|
| Clinical adverse events (AEs) ¹ | 11 (50.0%) | 13 (61.9%) | 15 (68.2%) |
| Related serious AEs | 1 (4.5%) | 0 (0%) | 0 (0%) |
| RCT discontinuation due to related AE | 0 (0%) | 0 (0%) | 0 (0%) |
| Infections | 10 (45.5%) | 5 (23.8%) | 6 (27.3%) |
| Related serious infections | 1 (4.5%) | 0 (0%) | 0 (0%) |
| Injection site reactions ² | 0 (0%) | 2 (9.5%) | 2 (9.1%) |
| Newly positive for anti-nuclear antibodies (ANA) ³ | 0 (0%) | 1 (5.9%) | 8 (36.4%) |
| Rashes | 0 (0%) | 0 (0%) | 0 (0%) |
| Arthralgia | 1 (4.5%) | 1 (4.8%) | 0 (0%) |

Comparable clinical safety profile to placebo with remarkably benign administration, no infection signal and no symptoms indicative of autoimmune activation or DIL⁴

1. Excludes events in the investigations System Organ Class (MedDRA).
2. All injection site reactions were mild to moderate.
3. Represents participants who were ANA negative at baseline and tested positive at $\geq 1:320$ at any point during RCT (percentages calculated from n=17 for 300mg arm and n=22 for 600mg arm). An ANA titer of $\geq 1:320$ was an exclusion criterion for the clinical trial protocol. At end of RCT (Week 13), 2 of the 8 patients in 600mg arm tested negative for ANA, 2 of the 8 patients in 600mg arm remained positive but at $< 1:320$.
4. Drug-Induced Lupus (DIL) is an autoimmune syndrome triggered by specific medications, such as statins, TNF-alpha inhibitors, and ACE inhibitors/beta-blockers. A key distinguishing feature of DIL is its reversibility, as symptoms typically resolve once the offending medication is withdrawn.




**Rationale for Q4W 300mg/2mL
Dosing & Potential for Enhanced,
Best-in-Class Efficacy in gMG**

OLE data support addition of 300mg/2mL Q4W in Ph. 3

PK levels approximately half of 300mg/2mL Q2W steady state resulted in robust reductions on MG-ADL & QMG


Mean Change in PBO Patients' MG-ADL and QMG Score from RCT Baseline to OLE Week 6



PBO Patients Entering OLE Received 600mg/4mL Q2W w/ No Loading Dose

- PK of ~65 µg/mL at week 4 after only two 600mg/4mL doses is substantially lower than steady state seen with 300mg/2mL dosing of ~100-120 µg/mL
- Robust reductions in MG-ADL and QMG are achieved by week 4, after just two 600mg/4mL doses and remain stable in subsequent weeks
- Growing external evidence further supports that lower levels of complement inhibition (<90%) may be sufficient for efficacy in gMG¹

Adding QMG screening criteria in Ph. 3, similar to zilucoplan Ph. 3¹, may better control for placebo response



Ph. 2 study did not include QMG inclusion criteria, similar to ravulizumab Ph. 3; post-hoc analysis of MaGic data demonstrates potentially best-in-class MG-ADL improvement in patients with QMG ≥ 10



The change from baseline in ADL was analyzed using a mixed effect model for repeated measures (MMRM) with treatment group, visit, treatment by visit interaction, stratification factors, and baseline measure included.

*One-sided p-values are presented for comparisons of claseprubart vs placebo, with any p-value below 0.1 considered nominally statistically significant.

1. Zilucoplan Ph. 3 MG trial had screening criteria of QMG ≥ 12 and MG-ADL ≥ 6 (<https://clinicaltrials.gov/study/NCT04115293>)

Potential for improved efficacy vs. C5 inhibitors with claseprubart may be due to upstream inhibition

Claseprubart Prevents the Creation of Pro-inflammatory Split Products C3a and C3b vs. Ravulizumab



Upstream inhibition prevents the creation of pro-inflammatory C3a and C3b as well as MAC, potentially providing additional efficacy benefits for AChR+ gMG patients

1. C3a Formation Assay: Human C3a ELISA specific to C3a-desArg with no cross-reactivity to C3 (N=3)

2. C3b Deposition Assay: Ab-sensitized hRBC triggered by complement-positive sera to deposit C3b on the hRBC surface, measured by flow cytometry (N=3)

*Enjaymo (sutimlimab) targets the C1s complement protein, which prevents C3b deposition on red blood cells, thereby stopping hemolysis and improving anemia in patients with cold agglutinin disease (Jager U, et al. Blood 2019;133:893-901)

EMERGE is a global Ph. 3 trial evaluating Q4W and Q2W S.C. claseprubart in AChR+ gMG; top-line data 2H'28


No ANA screening exclusion criteria or routine ANA testing during RCT or OLE, inclusion criteria of MG-ADL of ≥ 6 and QMG of ≥ 10 , and 17-week S.C. treatment period per alignment with FDA

Highlights

- **Design:** Male and female subjects randomized to receive either claseprubart or placebo for 17 weeks
- **Inclusion:** ≥ 18 years old with AChR antibody + gMG, **MG-ADL of ≥ 6 and QMG of ≥ 10**
- **Dosing:** I.V. Loading Dose followed by 300mg/2mL S.C. Q2W or **Q4W** starting Day 7
- **No ANA screening exclusion criteria or routine ANA testing** during the RCT or OLE

Endpoints

- **Primary:** MG-ADL change from baseline
- **Secondary / Exploratory:** Efficacy (QMG, MSE, MGC, MG-QoL-15r)



EMERGE 

Potential to further enhance best-in-class differentiation on efficacy and dosing convenience with QMG screening criteria and 300mg/2mL Q4W dosing

Achieving this profile could position claseprubart as a potential best-in-disease treatment for gMG



C5 OR SUPERIOR EFFICACY (ULTOMIRIS/SOLIRIS/ZILBRYSQ)

Similar or superior MG-ADL to FDA-approved C5 inhibitors with continuous, effective symptom control

Targeting >2-point MG-ADL improvement vs. placebo



C1s SAFETY (ENJAYMO)

Comparable *safety* to FDA-approved C1s & Classical Pathway inhibitor, leaving the lectin and alternative pathways intact

Targeting no Boxed Warning & REMS



AUTOINJECTOR CONVENIENCE (DUPIXENT)

Comparable *convenience* to DUPIXENT with one-click, self-administered SHL-Molly autoinjector



Targeting single 300mg/2mL S.C. Q2W or Q4W



**Claseprubart:
Opportunity to Change the
Treatment Paradigm in Chronic
Inflammatory Demyelinating
Polyneuropathy**

The US CIDP market offers substantial growth potential given high unmet need and limitations of current standard of care

Opportunity for an active C1s inhibitor with the target profile of claseprubart to replace the standard of care



Note: Positioning of claseprubart's target profile is illustrative. 1. Komodo claims data 2013-2025, adjusted to account for 70% capture of real-world patient counts for biologic treated patients, adjusted to account for 27% misdiagnosed. 2. Argenx Vyvgart Hytrulo HCP website. 3. Fierce Pharma, CIDP Pricing. 4. Argenx 4Q 2025 Financial Results, Feb 26, 2026. 5. Based on Dianthus market research and estimates. 6. Based on EvaluatePharma (Jan '26), Immunoglobulin – Global Market Analysis, Fortune Business Insights, and Dianthus market research and estimates. Assumes Ig price per patient of ~\$150,000 per year and average biologic net price per patient of ~\$700,000 per year.

Survey of US Neurologists supports potential transformative opportunity in CIDP

Claseprubart aims to differentiate and effectively address the significant unmet needs in the CIDP market



Total Neurologists 80

Neuromuscular Specialist 81%

Generalist 19%

Academic 58%

Community based 42%



Sample Demographics

~13 years in active clinical practice (post-residency), on average

~90% of professional time spent providing direct patient care, on average

~60 CIDP patients seen in the past 12 months, on average

~79%

of Neurologists strongly believe patients prefer treatments with **more consistent and sustained symptom control**

~66%

of Neurologists strongly believe there is high unmet need for therapies with **greater efficacy**

~54%

of Neurologists strongly prefer treatment options **without a boxed warning or REMS program**


~75%

of Neurologists strongly believe patients prefer therapies that are **more convenient and easier to administer**



Surveyed Neurologists want safer, more effective and convenient treatment options than IVIg for CIDP patients

Overall, surveyed Neurologists believe ~50% patients on IVIg have partial or no response to treatment



Dianthus 2026 Neurologist CIDP and MMN quantitative survey (n=80, N = 65 Neuromuscular specialists, N = 15 General Neurologists), fielded Q1
Data represents % of Neurologists selecting 7-9 on a 9-pt. agreement scale


Interim Responder Analysis in CAPTIVATE was planned with first 40 patients completing Open-Label Part A

Highlights

- **Design:** All subjects receive claseprubart in Part A for up to 13 weeks. Only responders randomized to Part B for 52 weeks
- **Inclusion:** ≥18 years old with confirmed CIDP, including SoC-Refractory, SoC-Treated or SoC-Naïve
- **Dosing:** I.V. Loading Dose followed by 300mg/2mL S.C. Q2W in Part A; followed by 300mg/2mL or 600mg/4mL or placebo in Part B

Endpoints

- **Part A:** Response as measured as ≥1 point decrease (improvement) in adjusted INCAT score compared to Part A baseline
- **Part B Primary:** Efficacy (time to relapse) as measured as ≥1 point increase in adjusted INCAT



CAPTIVATE Trial: <https://clinicaltrials.gov/study/NCT06858579>.



Single pivotal two-part, randomized withdrawal, double-blind, placebo-controlled trial designed to support BLA in adult patients with CIDP



Enrolling a broad patient population including SoC-refractory patients, in addition to SoC-Treated and SoC-Naïve patients











No requirement for IVIg withdrawal and disease worsening, consistent with ongoing FcRn and complement CIDP studies



Only responders from Part A randomized into the double-blind, placebo-controlled Part B

Significant differences between CAPTIVATE and ADHERE

| Considerations | Efgartigimod (FcRn) S.C. QW | Claseprubart (aC1s) 300mg/2mL S.C. Q2W | Key Differentiators of CAPTIVATE |
|---|--|---|---|
|  Ph. 3 Study Populations |  SoC-Treated Off Treatment |  SoC-Treated SoC-Naïve SoC-Refractory |  Evaluating claseprubart in SoC-Refractory CIDP patients , in addition to a broader CIDP patient population including SoC-Treated and SoC-Naïve |
|  Require IVIg or SCIg Withdrawal and Relapse Prior to Enrolling in Part A of Study¹ | YES | NO |  Immediate switch 7 days from last Ig dose to claseprubart ; consistent with other ongoing complement CIDP studies ³ |
|  Study Endpoints / Results | <ul style="list-style-type: none"> • Confirmed ECI² • Ph. 3 Stage A results: -66.5% ECI (wk 12) | <ul style="list-style-type: none"> • Switching Ig patients to claseprubart 7 days after last dose • Aiming for ≥1-point adj. INCAT improvement OVER SoC/Ig in ≥50% of patients in Part A |  Part A designed to evaluate clinically meaningful improvement over Ig after immediate switch 7 days after last dose |

~1/3 of pts did not return to pre-Ig washout baseline

Source: Company filings, presentations and clinicaltrials.gov.

Ig refers to IVIg and SCIg

Data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted.


1. ADHERE required discontinuation of IVIg or SCIg and evidence of clinically meaningful deterioration before dosing in Part A

2. Defined as a clinical improvement on the parameters that the participant worsened in during run-in (≥4-point increase in I-RODS and/or ≥8-kPa increase in mean grip strength) or clinical improvement (≥1-point decrease) in INCAT

3. Empasiprubart and riliprubart studies

Active C1s inhibition with riliprubart has demonstrated clinical proof-of-concept across broad patient groups

Ph. 2 Riliprubart Data in Active C1s in CIDP¹ with High Volume, Weekly Dosing of 600mg/4mL²



Claseprubart is being evaluated with a convenient, low volume dose of 300mg/2mL Q2W

1. Riliprubart Phase 2 at PNS 2024
2. Based on riliprubart patent filing (Pg 76)


Claseprubart in vitro affinity and potency

Affinity assays

| | | DNTH103 | riliprubart | Fold Improvement |
|---|--------|---------|-------------|------------------|
| Binding Affinity to human active C1s (K_D) ¹ | KinExa | 9pM | 75pM | ~8X |
| | SPR | 8pM | 35pM | ~4X |


Enzymatic assay

C4 cleavage by human active C1s²




Functional assays of classical pathway inhibition


Wieslab classical pathway Assay in human serum³



CH50 assay of RBC lysis in human serum³



Liposome lysis in human serum³



Claseprubart has consistently higher affinity and stronger potency in multiple head-to-head *in vitro* experiments

Note: Riliprubart is produced using sequence from patent WO2018071676A1

1. Data shown is dissociation constant (K_D) and the average of 3 different experiments performed at independent laboratories.

2. Data is quantitative analysis of active C1s protease inhibition of cleaved C4 fragments in the presence of claseprubart or riliprubart.

3. Data shown are the average of 3 experiments conducted for each of the functional assays (CH50 hemolysis, Wieslab and Liposome). CH50 and Wieslab were confirmed at independent laboratories.

Announced early GO decision reached with less than 40 planned participants completing Part A in March'26

CAPTIVATE Interim Analysis Objective



Targeting response rate of 50% or greater (≥ 20 patients out of first 40 participants in Part A) based on precedent set with aC1s inhibition

GO Decision



GO decision reached early after 20 confirmed responders were achieved with less than 40 planned participants completing Part A

Safety / Tolerability Update




Independent DSMB reviewed the data to date and confirmed GO decision; no related serious infections, no clinical symptoms of autoimmune activation or DIL, no related SAEs or discontinuations


GO decision supports continued development of claseprubart at 300mg/2mL Q2W S.C. in CIDP targeting a potentially best-in-disease biologic profile

CAPTIVATE Part A baseline patient group characteristics are similar to precedent aC1s Ph. 2 study¹

Riliprubart Ph. 2¹
Baseline Patient Group Characteristics (N=78)



CAPTIVATE²
Baseline Patient Group Characteristics









Broad representation of patients across North America, Europe, and Asia in CAPTIVATE Part A

Data from CAPTIVATE and riliprubart Ph. 2 are derived from different clinical trials conducted at different times, with differences in trial design and patient populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted.

1. [Riliprubart Phase 2 at PNS 2024](#)
2. Includes only participants who have completed Part A. Data cut off as of March 4, 2026

Early responder rates support 300mg/2mL Q2W dose and updates to CAPTIVATE

| Trial Design Element | Original Design | Anticipated New Design | Claseprubart CAPTIVATE Implications |
|---|--|---|--|
|  Part A Dose | <ul style="list-style-type: none"> • 300mg/2mL S.C. Q2W | <ul style="list-style-type: none"> • 300mg/2mL S.C. Q2W |  No change to Part A dose given results observed to date |
|  Study Arms in Part B | <ol style="list-style-type: none"> 1. 300mg/2mL Q2W (N=64) 2. 600mg/4mL Q2W (N=64) 3. Placebo (N=64) <ul style="list-style-type: none"> • <i>Total Part B Patients (N=192)</i> | <ol style="list-style-type: none"> 1. 300mg/2mL Q2W (N=64) 2. Placebo (N=64) <ul style="list-style-type: none"> • <i>Total Part B Patients (N=128)</i> |  ~1/3 fewer total patients anticipated in Part B and potential faster execution to top-line results |
|  Estimated Enrollment in Part A | <p>Up to 480 patients, conservative 40% minimum responder rates</p> | <p>Up to 256 patients, conservative 50% minimum responder rates</p> |  Ratio from Part A to Part B changed due to responder rates seen across all patient groups |


Revised CAPTIVATE study design going forward

Highlights

- **Design:** All subjects receive claseprubart in Part A for up to 13 weeks. Only responders randomized to Part B for 52 weeks
- **Inclusion:** ≥18 years old with confirmed CIDP, including SoC-Refractory, SoC-Treated or SoC-Naïve
- **Dosing:** I.V. Loading Dose followed by 300mg/2mL S.C. Q2W in Part A; followed by 300mg/2mL or placebo in Part B
- **No ANA screening exclusion criteria or routine ANA testing** during the RCT or OLE

Endpoints

- **Part A:** Response as measured as ≥1 point decrease (improvement) in adjusted INCAT score compared to Part A baseline
- **Part B Primary:** Efficacy (time to relapse) as measured as ≥1 point increase in adjusted INCAT



Planned changes pending regulatory approval

Achieving this target profile could position claseprubart as a potential blockbuster treatment for CIDP



EFFICACY (IVIg/SCIg)

Improvement over SoC (i.e. Ig) with continuous, effective symptom control

Targeting Best-in-Class or Best-in-Disease Efficacy



C1s SAFETY (ENJAYMO)

Comparable *safety* to FDA-approved C1s & Classical Pathway inhibitor, leaving the lectin and alternative pathways intact

Targeting no Boxed Warning & REMS



AUTOINJECTOR CONVENIENCE (DUPIXENT)

Most *convenient* therapy with self-administered SHL-Molly autoinjector



Targeting single 300mg/2mL S.C. Q2W

The slide features several abstract, organic shapes in a deep maroon color on the left side. These shapes are layered, with some appearing behind others, creating a sense of depth. The largest shape is a broad, curved form that starts near the top left and extends downwards. Below it, there's a smaller, more pointed shape. At the bottom, there's another shape that looks like a small, upward-pointing triangle or a pointed oval. The overall effect is a modern, graphic design element.

**Claseprubart:
Opportunity to be Best-in-Class
in Multifocal Motor Neuropathy**

The US MMN market is underdiagnosed with a need for more effective and convenient treatment options

Opportunity for the target profile of claseprubart to become the new standard of care in MMN



Note: Positioning of claseprubart's target profile is illustrative. 1. 2024 patients projected from 2023 count due to unreliable 2024 data from the Change Healthcare cyber-attack. 2. Komodo claims data 2013-2025, adjusted to account for 70% capture of real-world patient counts. 3. Dianthus market research and estimates. 4. Based on EvaluatePharma (Jan '26), Immunoglobulin – Global Market Analysis, Fortune Business Insights, and Dianthus market research and estimates. Assumes Ig price per patient of ~\$150,000 per year and average biologic net price per patient of ~\$700,000 per year.

Survey of US Neurologists supports MMN underdiagnosis and lack of effective treatment options

Claseprubart aims to address the significant unmet needs in the underdiagnosed MMN market



Total Neurologists 80

Neuromuscular Specialist 81%

Generalist 19%

Academic 58%

Community based 42%



Sample Demographics

~13 years in active clinical practice (post-residency), on average

~90% of professional time spent providing direct patient care, on average

~25 MMN patients seen in the past 12 months (median)

~81%

of Neurologists strongly believe that MMN is an **underdiagnosed condition**

~73%

of Neurologists strongly believe there is a high unmet need for **therapies with meaningful clinical improvement**



~68%

of Neurologists strongly believe that treatment options **without boxed warnings or REMS are preferred**

~63%

of Neurologists strongly believe there is a high unmet need **for therapies with a more favorable dosing schedule**

Surveyed Neurologists want safer, more effective and convenient treatment options than IVIg for MMN patients

Overall, surveyed Neurologists believe ~50% patients on IVIg have partial or no response to treatment

% of Surveyed Neurologists Who Strongly Believe...



Patients on IVIg often report **residual or unaddressed symptoms**



Clinical efficacy of IVIg remains is **incomplete, inconsistent, and/or short-lived**




Despite SoC, **1/3 of patients remain refractory** and face **risk of clinical deterioration**



Current **label warnings/risks** for IVIg are **important in their treatment decisions**

MMN is an attractive opportunity with clinical PoC demonstrated via classical pathway inhibition

Empasiprubart (Q1-2W I.V., C2 inhibitor) Ph. 2 Data Demonstrating Efficacy Signals¹



“We hypothesize that targeting the **classical complement pathway is a potential therapeutic approach in MMN**. We investigated the interaction of circulating anti-GM1 IgM from patients with MMN with complement in detail using iPSC-derived MNs. In this disease model for MMN, we evaluated the effects of ARGX-117, a novel monoclonal antibody that inhibits complement factor C2.” - *Neuro/Neuroimmunol Neuroinflamm.* 2022 Jan; 9(1): e1107



Phase 2 trial of claseprubart, a low-volume Q2W S.C., ongoing in MMN

1. https://argenx.com/content/dam/argenx-corp/events-presentations/argenx_RnD_Day_2024_Slides.pdf#/page=127

Claseprubart demonstrates superior classical pathway potency vs. empasiprubart

Empasiprubart Published Classical Pathway Potency Data Using the Quidel MicroVue CH50¹

Claseprubart Demonstrates Superior Classical Pathway Potency Head-to-head vs. Empasiprubart Using Same Assay









“ARGX-117 potently inhibited CP and LP (half-maximal effective concentration [EC₅₀] = 30.5 ± 4.5 and 93.4 ± 10.4 µg/mL, respectively) in a concentration-dependent manner” – *Journal of Allergy and Clinical Immunology*

| | claseprubart | empasiprubart |
|--------------------------|--------------|---------------|
| IC ₅₀ (µg/mL) | 3.8 ± 0.8 | 22.1 ± 5.7 |
| IC ₉₀ (µg/mL) | 9.9 ± 2.5 | 375 ± 266 |

Claseprubart and empasiprubart are investigational agents that are not approved as therapies for MMN or any indication in any jurisdiction worldwide. Head-to-head data shown are the average of 3 experiments conducted for claseprubart and 8 experiments conducted for empasiprubart. Empasiprubart in the head-to-head experiment is produced using the sequence published in the IMGT database (DB card 12277). EC₅₀ and IC₅₀ can be considered as interchangeable for this analysis

1. *Journal of Allergy and Clinical Immunology*, Volume 147, Issue 4, 1420 - 1429.e7

Claseprubart has the potential to dominate the MMN market with its best-in-class target product profile

| Considerations | Empasiprubart (C2)* | Claseprubart (active C1s)* | Key Differentiators of Claseprubart |
|--|---|---|---|
|  MMN is an IgM and classical pathway driven disease ¹ | Published classical pathway ³ EC ₅₀ = 30.5 ±4.5 µg/mL using Quidel MicroVue CH50 | Claseprubart has demonstrated potent inhibition of classical pathway in multiple assays |  ~6x more potent than empasiprubart on IC ₅₀ in head-to-head in-vitro experiment using Quidel MicroVue CH50 |
|  Lectin pathway inhibition not required for efficacy in MMN | Published lectin pathway ³ inhibition of EC ₅₀ = 93.4 ±10.4 µg/mL | Does not inhibit lectin pathway |  Claseprubart preserves key bacterial killing role of lectin pathway ² |
|  Patients prefer convenient therapies | I.V. Q4W | Targeting Q2W self-administration via 300mg/2mL S.C. autoinjector |  More convenient by targeting infrequent, low volume, self-administered S.C. autoinjector |

Claseprubart has the potential to be the first-line targeted biologic treatment given its unique combination of classical pathway potency, preservation of the lectin pathway, and dosing convenience

* Claseprubart and empasiprubart are investigational agents that are not approved as therapies for MMN or any indication in any jurisdiction worldwide. EC₅₀ and IC₅₀ can be considered as interchangeable for this analysis

1. Budding et al., (2021). *Neurol Neuroimmunol Neuroinflamm.* 9(1):e1107; Vlam et al., (2015). *Neurol Neuroimmunol Neuroinflamm.* 2015;2(4):e119; 2. Ali et al., (2012). *PLoS Pathog* 8(7):e1002793 3. *Journal of Allergy and Clinical Immunology*, Volume 147, Issue 4, 1420 - 1429.e7.

Phase 2 MoMeNtum top-line data in MMN anticipated 2H'26


A global, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and PK / PD of claseprubart administered S.C. following initial loading dose

Highlights

- **Design:** 36 participants randomized to receive either claseprubart or placebo for 17 weeks
- **Inclusion:** ≥18 years old with MMN who are immunoglobulin responsive and dependent
- **Dosing:** I.V. Loading Dose followed by 300mg/2mL or 600mg/4mL S.C. Q2W starting Day 7
- **No ANA screening exclusion criteria or routine ANA testing** during the RCT or OLE

Endpoints

- **Primary:** Safety
- **Secondary:** Efficacy (time to IVIg retreatment, time to relapse, grip strength and other muscle strength and motor function measurements)



MOMENTUM




Top-line data expected in 2H'26



**DNTH212:
Potential Best-in-Class
Bispecific Fusion Protein for
Multiple Autoimmune Indications**

DNTH212 is a bifunctional BDCA2 and BAFF/APRIL inhibitor targeting two validated pathways

- Inhibiting BDCA2 reduces Type 1 interferon production from plasmacytoid dendritic cells (pDCs)
- Single CRD2 domain of TACI designed to deliver robust B cell modulation via BAFF/APRIL inhibition



DNTH212 targets both the innate and adaptive immune systems with complementary disease modifying mechanisms enabling potential best-in-class efficacy


Potential to drive superior clinical efficacy by targeting both the innate and adaptive immune systems

Innate Immune System: Plasmacytoid Dendritic Cells (pDCs)

- Key cell type producing Type 1 interferon
- Promote B cell proliferation and Ig secretion through antigen presentation and production of BAFF
- Direct and indirect activation of other innate and adaptive immune cells
- Type 1 interferon inhibition has been shown effective in multiple autoimmune diseases



Adaptive Immune System: B Cells

- Generate autoantibodies, forming immune complexes that trigger inflammation and tissue damage
- Inhibiting BAFF/APRIL has been shown effective in multiple autoimmune diseases



Bifunctional approach addressing autoimmune diseases where both Type 1 interferon and B Cells are implicated has strong mechanistic rationale for potential best-in-class efficacy

DNTH212 achieves superior pDC depletion compared to litifilimab *in vitro*




pDC depletion removes a key cell type involved in Type 1 interferon production and activation of other immune cells which contribute to disease


1. Method: Human PBMCs from a healthy donor were co-cultured with a TLR9 agonist and serially diluted antibodies for 24 hours. IFN- α release in the supernatant was measured using an HTRF kit
2. Method: Human PBMCs from a healthy donor were co-cultured with serially diluted antibodies for 24 hours. pDC counts were assessed via flow cytometry

DNTH212 shows superior inhibition of IgM, IgA, and IgG compared to povetacicept following single dose in NHPs

S.C. DNTH212



IV povetacicept and telitacicept¹



Deeper Ig reductions have potential to drive superior clinical efficacy while maintaining at least Q4W dosing

Note: These data are derived from different studies at different points in time, with differences in methodology, design and populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials of DNTH212 and other agents have been conducted

1. Arthritis Rheumatol.2023 Jul;75(7):1187-1202. Note: WT TACI (13-118) Fc:Telitacicept


Validation of both BDCA2 and BAFF/APRIL targeted therapies support DNTH212 bifunctional approach

Positive Litifilimab (BDCA2) Data in SLE / CLE

PART A OF THE PHASE 2 LILAC STUDY MET ITS PRIMARY ENDPOINT

Improved Joint Activity: Litifilimab significantly reduced the mean total number of active joints vs placebo


Total active joint count**† in patients with SLE and active skin disease and joint involvement (N=132†) (primary endpoint at Week 24)¹



PART B OF THE PHASE 2 LILAC STUDY MET ITS PRIMARY ENDPOINT IN CLE PATIENTS WITH OR WITHOUT SYSTEMIC MANIFESTATIONS

Litifilimab significantly reduced skin disease activity vs placebo, on top of standard of care

Percentage change in CLASI-A score from baseline over time (primary endpoint at Week 16)*



Observed consistent safety profile with no new safety signals

*Mixed-effects model for repeated measurements; †P<0.05 versus placebo; ‡P<0.001 versus placebo
CLASI-A = Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity; CLE = cutaneous lupus erythematosus; CI = confidence interval; LSM = least squares mean; SE = standard error
1. Werth VP, et al. N Engl J Med 2022;387:324-331



BAFF/APRIL Validation Across Multiple Autoimmune Indications and Strategic Activity



Commercial Approvals

Validated Commercial Therapy in China Across Diverse Autoimmune Diseases

2021 - Systemic Lupus Erythematosus (SLE)[†]
2024 - Rheumatoid Arthritis (RA)
2025 - Myasthenia Gravis (MG)

BLA Submissions

Filed to Further Expand Telitaccept Footprint in Large, Underserved Diseases in China

Est. 2026 - Primary Sjögren's Disease (pSD)
Est. 2026 - IgA Nephropathy (IgAN)[†]

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

June 25, 2025

- Vor Bio receive development for



Telitaccept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease

August 13, 2025

Phase 3 results position telitaccept as potential best-in-disease profile in primary Sjögren's disease

Telitaccept demonstrated a favorable safety profile



Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

April 10, 2024

- Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies -

- Alpine's lead product, povetacept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 -

- Povetacept holds promise as a pipeline-in-a-product, with clinical studies in additional serious diseases underway -

- Alpine's protein engineering and immunotherapy expertise augments Vertex's toolbox and capabilities -

- Vertex to host investor call today, April 10, at 4:30 pm ET -

BOSTON & SEATTLE--(BUSINESS WIRE)--Apr. 10, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for \$65 per share or approximately \$4.9 billion in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close later this quarter.

Broad opportunity for DNTH212 across multiple diseases where Type 1 interferon and B Cells are implicated

Indications with biological rationale and supportive clinical data

| | Biological Rationale | Clinical Evidence |
|--|----------------------|---|
| Primary Sjögren's Syndrome ~350,000 U.S. Patients | ✓ | <ul style="list-style-type: none"> <i>B Cell</i>: ianalumab positive Ph. 3; telitacept positive Ph. 3 |
| Cutaneous Lupus Erythematosus ~300,000 U.S. Patients | ✓ | <ul style="list-style-type: none"> <i>Type 1 interferon</i>: litifilimab positive Ph. 2 |
| Systemic Lupus Erythematosus ~225,000 U.S. Patients | ✓ | <ul style="list-style-type: none"> <i>Type 1 interferon</i>: anifrolumab approved; litifilimab positive Ph. 2 <i>B Cell</i>: belimumab approved; telitacept approved (CN); ianalumab positive Ph. 2 |
| Lupus Nephritis ~120,000 U.S. Patients | ✓ | <ul style="list-style-type: none"> <i>B Cell</i>: belimumab approved |
| Dermatomyositis ~50,000 U.S. Patients | ✓ | <ul style="list-style-type: none"> <i>Type 1 interferon</i>: dazukibart positive Ph. 2 |

Indications with biological rationale

| | Biological Rationale |
|---|----------------------|
| Hidradenitis Suppurativa ~330,000 U.S. Patients | ✓ |
| Scleroderma ~75,000 U.S. Patients | ✓ |
| Pemphigus Vulgaris ~32,000 U.S. Patients | ✓ |

Dianthus to provide update on indication prioritization in 1H 2026

Ph. 1 study initiated in China in Dec. '25 with top-line Part A HV results anticipated in 2H'26

Healthy Volunteers (Part A)

~46 HVs enrolled into seven cohorts:

- Treated (N= up to 6)
- Placebo (N= up to 2)

SLE Patients (Part B)

~30 patients enrolled into three cohorts:


- Treated (N= up to 10)

Key Parameters

- Safety, PK, and PD as well as other biomarkers and preliminary efficacy


Healthy Volunteers (Part A)

S.C. Administration



SLE Patients (Part B)

S.C. Administration



Phase 1 trial designed to evaluate safety, tolerability and PK/PD

DNTH212 TPP aims to deliver superior efficacy in a safe and well-tolerated therapy with patient friendly convenience



EFFICACY

Bifunctional approach has potential for *superior* efficacy in various disease states versus only targeting innate or adaptive immune system



SAFETY

Inhibiting Type 1 interferon or BAFF/APRIL has been generally safe and well tolerated




CONVENIENCE

Targeting patient friendly S.C. self-administration with Q4W or less frequent dosing

Achieving the TPP would position DNTH212 as a first-line biologic across a range of indications

Achieving DNTH212 TPP would position DNTH212 as a first-line, best-in-class therapy across multiple indications



The slide features several abstract, organic shapes in a deep maroon color on the left side. These shapes are layered, with some appearing behind others, creating a sense of depth. The largest shape is a broad, curved form that starts near the top left and extends downwards. Below it, there's a smaller, more pointed shape. At the bottom, there's another shape that looks like a smaller, more defined version of the top one. The overall effect is a modern, artistic background element.

Recap of Dianthus Leadership in Severe Autoimmune Diseases

Advancing a leading autoimmune-focused biotech with two clinical stage programs

| Program | Indication | Ph. 1 | Ph. 2 | Ph. 3 | Upcoming Milestones |
|------------------------------------|------------------------------------|-------|-------|-------|---|
| Claseprubart aC1s | gMG >100,000 U.S. Patients | | | | <ul style="list-style-type: none"> Initiation of Ph. 3 study expected in mid-26 Ph. 3 top-line data expected in 2H'28 |
| | CIDP >40,000 U.S. Patients | | | | <ul style="list-style-type: none"> Part B top-line guidance expected by YE'26 Peer Milestone: riliprubart Ph. 3 MOBILIZE and VITALIZE (H2H vs. IVIg) data expected in 2027³ |
| | MMN >10,000 U.S. Patients | | | | <ul style="list-style-type: none"> Ph. 2 top-line data expected in 2H'26 Peer Milestone: empasiprubart Ph. 3 data expected in Q4'26⁴ |
| DNTH212 BDCA2 and BAFF/APRIL | Multiple Autoimmune Diseases | | | | <ul style="list-style-type: none"> Healthy volunteers (Part A) SLE patients (Part B) Update on indication prioritization expected in 1H'26 Ph. 1 HV top-line data expected in 2H'26 |

Strong balance sheet with ~\$1.2B¹ of cash & runway expected into 2030
~55.3M shares outstanding²


1. Pro forma cash includes cash, cash equivalents and investments of ~\$514M as of 12/31/25 plus estimated net proceeds of ~\$676M from the March 2026 follow-on offering
2. Pro forma shares includes 44.5M shares outstanding as of March 4, 2026 and assumes the exercise of all outstanding pre-funded warrants as of 12/31/25 plus 8.9M shares and pre-funded warrants issued in the March 2026 follow-on offering
3. Based on Sanofi Q4'25 financial results presentation
4. Based on publicly available information: <https://argenx.com/news/2026/press-release-3216531>

The left side of the page features several overlapping, curved shapes in a dark maroon color. These shapes are abstract and organic, creating a modern, layered effect. The largest shape is a broad, sweeping curve that starts from the top left and extends towards the center. Below it, there are smaller, more pointed shapes that also curve towards the center, creating a sense of depth and movement.

Appendix

Selectively targeting classical pathway aims to provide effective but safer complement inhibitor

Targeting aC1s aims to deliver efficacy demonstrated with terminal inhibitors while preserving the critical immune activity of lectin and alternative pathways, leading to a lower risk of infection and no FDA boxed warning/REMS



Unlike C5 inhibitors, ENJAYMO® has no FDA boxed warning and REMS, or prophylactic antibiotic requirement prior to vaccination



C5 inhibitor

✗ Boxed Warning and REMS

ULTOMIRIS® (ravulizumab-cwvz) injection, for intravenous or subcutaneous use
Initial U.S. Approval: 2018

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS
See full prescribing information for complete boxed warning.

ULTOMIRIS increases the risk of serious and life-threatening infections caused by *Neisseria meningitidis*.

- Complete or update meningococcal vaccination at least 2 weeks prior to the first dose of ULTOMIRIS, unless the risks of delaying ULTOMIRIS outweigh the risks of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients receiving a complement inhibitor. (5.1)
- Patients receiving ULTOMIRIS are at increased risk for invasive disease caused by *N. meningitidis*, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of meningococcal infections and evaluate immediately if infection is suspected. (5.1)

ULTOMIRIS is available only through a restricted program called ULTOMIRIS and SOLIRIS REMS. (5.2)

✗ Antibiotic Prophylaxis Required if not Fully Vaccinated

2.2 Recommended Vaccination and Prophylaxis for Meningococcal Infection

Vaccinate patients against meningococcal infection (serogroups A, C, W, Y and B) according to current ACIP recommendations at least 2 weeks prior to initiation of ULTOMIRIS [see Warnings and Precautions (5.1)].

If urgent ULTOMIRIS therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible.

Healthcare providers who prescribe ULTOMIRIS must enroll in the ULTOMIRIS and SOLIRIS REMS [see Warnings and Precautions (5.2)].



C1s inhibitor


✓ No Boxed Warning or REMS

✓ No Antibiotic Prophylaxis Required

Claseprubart *in vitro* study indicates lower risk of *Neisseria meningitidis* infections

- Protection against infection is a critical function of the complement pathway
- **DNTH103 selectively inhibits** the **classical pathway**, leaving the alternative and lectin-activated defense pathways intact
- An *in vitro* assay measured **antibody-dependent complement-mediated killing of *N. meningitidis*** in the presence of **DNTH103** and **anti-C5 (ravulizumab*)**
- In this assay, **DNTH103 maintained bacterial killing**, potentially leading to a decreased risk of infection vs. C5 inhibitors

Anti-capsular antibody (Anti -Nm) mimics *N. meningitidis* vaccination




Results further validate the potential differentiated safety profile for DNTH103 as a selective classical pathway inhibitor consistent with ENJAYMO, an approved C1s inhibitor without an FDA Boxed Warning or REMS


Claseprubart aims to provide consistent symptom control with convenient Q2W S.C. dosing

- Chronic diseases like MG benefit from **consistent treatment and symptom control**
- When patients are required to take a drug holiday on FcRns, **MG-ADL scores immediately begin to rebound** as patients self-report symptoms and disease worsening
- Real-world evidence¹ suggests **sustained inhibition / treatment with complement is better over time**

VYVGART®: Cyclic Dosing Leads to MG-ADL Rebound



ULTOMIRIS®: Complement Inhibition Provides Consistent MG-ADL Symptom Control



▲ Indicates VYVGART® dose administered


Source: VYVGART® [prescribing information](#) and ULTOMIRIS® [prescribing information](#)

1. Pane et al. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. *J Neurol* 271, 6209–6219 (2024)

Real-world evidence demonstrates clinical advantages for complement vs. FcRns


Real-world Evidence Indicates Sustained MG-ADL Reductions for Complement Inhibitors vs. FcRns, Among Other Clinical Benefits

- **Patients on eculizumab showed a greater reduction in MG-ADL** over time than those on efgartigimod
- **Eculizumab showed statistically significant, deeper QMG reduction** and higher responder rate than efgartigimod
- **Eculizumab patients had a statistically significant greater reduction in rate of clinical events** (deteriorations, crisis or hospitalization) than efgartigimod
- **Patients on efgartigimod were more likely to suspend treatment** ($p = 0.015$ for AChR+ patients) with the “main reason for discontinuation was MG deterioration”
- **Eculizumab patients also had a statistically significant greater reduction in steroid dose** coming from a higher baseline dose vs. efgartigimod patients, but reaching a numerically lower dose during the treatment period



Claseprubart improves neurotransmission and muscle contraction in an AChR+ MG model


- **Serum from MG patients** used in a validated in vitro MG model^{1,2,3}
- **Assessed improvement in neurotransmission and muscle contraction** of ravulizumab* and DNTH103, as measured by decrease in muscle contraction fatigue
- **Results confirm DNTH103 improved neurotransmission and muscle contraction**



Results provide further scientific rationale for DNTH103 in gMG

Claseprubart restores neuronal conduction velocity in an *in vitro* CIDP model

- **Serum from 3 CIDP patients** was evaluated in a , commercially available *in vitro* CIDP model¹
- **Assessed improvement in neuronal conduction velocity** of two doses of DNTH103 as compared to baseline conduction velocity determined in sera from healthy volunteers (N=3)
- **Results confirm DNTH103 completely restored conduction velocity** across the axons of human motor neurons in the presence of autoantibodies from CIDP patient sera



Results provide further scientific rationale for DNTH103 in CIDP

Claseprubart Phase 1 healthy volunteer study was designed to validate extended half-life, potency and safety

SAD

44 HVs enrolled into six cohorts:

- Placebo (N= up to 2)
- Treated (N= up to 6)


MAD

16 HVs enrolled into two cohorts:

- Placebo (N= up to 2)
- Treated (N= up to 6)

Key Parameters


- Safety, PK, and PD measured by percent classical pathway inhibition quantified in each cohort




60 healthy volunteers completed dosing as of December 2023 across these eight cohorts

Claseprubart has demonstrated deep and sustained complement inhibition in healthy volunteers


I.V. SAD:
Linear PK with Exposure Proportional
Across Doses



S.C. MAD:
Strong Accumulation with Q2W Dosing



PK/PD:
Analysis Demonstrates IC90 of 87 µg/mL



Claseprubart demonstrated a ~60-day half-life and IC90 of 87 µg/mL


Phase 1 data estimated IC90 at ~87 µg/mL, leading to target dose of 300mg/2mL in Ph. 2 to achieve steady state >IC90

Ph. 1 Data Confirms

- ~60-day half-life
- IC90 calculated at 87 µg/mL

Dosing Modeled

- 15mg/kg I.V. on Day 0
- 300mg S.C. Q2W starting Day 7



Simulation using data from 60 healthy volunteers dosed across multiple cohorts demonstrates 300mg/2ml Q2W achieves steady state above target inhibition of IC90 at 87 µg/mL

Claseprubart was generally well tolerated, with a favorable safety profile in Phase 1

- No standard safety lab findings (hematology, chemistry, coagulation LFTS and renal function)
- No serious adverse events
- No infection adverse event signal and no infections related to encapsulated bacteria

| | I.V. & S.C. SAD (n=44) | | | S.C. MAD (n=16) | |
|--------------------------|----------------------------|----------------------------|-----------------------------------|----------------------------|---------------------------|
| | Pooled DNTH103 I.V. (n=21) | Pooled DNTH103 S.C. (n=12) | Pooled Placebo I.V. / S.C. (n=11) | Pooled DNTH103 S.C. (n=12) | Pooled Placebo S.C. (n=4) |
| Participant with: | | | | | |
| Any AEs | 13 (62%) | 9 (75%) | 7 (64%) | 8 (67%) | 4 (100%) |
| Any SAEs | 0 | 0 | 0 | 0 | 0 |
| Grade 3 / 4 AEs | 0 | 0 | 0 | 0 | 0 |
| Treatment Related AEs | 2 (10%) | 1 (8%) | 0 | 2 (17%) | 0 |


- Five participants experienced mild/moderate Treatment Related AEs
 - Two participants (one in each 300mg/2mL and 600mg/4mL S.C. MAD cohorts) had a mild or moderate injection site reactions (ISRs); no intervention was required and both participants completed treatment
 - One participant experienced several non-specific AEs during infusion; infusion was paused for 8 minutes and restarted at the same rate without sequelae
 - Two participants in 50mg/kg SAD I.V.¹ cohort became ANA² positive at Day 57; both participants had no evidence of SLE and both tested negative for dsDNA³
 - One participant in 600mg/4mL S.C. SAD reported vomiting on Day 1, which resolved on same day

¹ Highest dose used in Phase 2 trial was single I.V. loading dose of 20mg/kg

² Non-specific indicator of autoimmune disease present in up to 25% of healthy individuals: <https://www.labcorp.com/assets-media/2785>

³ Anti-double-stranded deoxyribonucleic acid antibodies are highly specific markers of systemic lupus erythematosus or SLE.

Pro-inflammatory split products C3a and C3b have potential negative effects on NMJ pathology beyond MAC in gMG









C3a and C3b Are Elevated in AChR+ gMG – Both Cause Inflammatory Damage^{1,2}

| C3a | C3b |
|---|--|
| <ul style="list-style-type: none"> Anaphylotoxin^{2,3} Initiates mast cell degranulation⁴ Promotes neutrophil-mediated acute phase reactions⁵ driven by pro-inflammatory cytokines⁶ – particularly IL-6 in gMG⁷ Has the potential to directly act on NMJ via smooth muscle contraction and endothelial permeability⁸ | <ul style="list-style-type: none"> Opsonin³ Forms part of an amplification loop that perpetuates a cycle of complement activation³ Facilitates integrin-mediated phagocytosis³ |

Ab, antibody; gMG, generalized myasthenia gravis; IL, interleukin; MAC, membrane attack complex; NMJ, neuromuscular junction

1. Stascheit F, et al. *Eur J Neurol* 2023;30:1409–16; 2. Iacomino N, et al. *Biomedicines* 2022;10; 3. Watanabe-Kusunoki K, Anders HJ. *J Autoimmun* 2024;145:103216; 4. Nilsson G, et al. *J Immunol* 1996;157:1693–8; 5. Riaz B, Sohn S. *Cells* 2023;12; 6. Wang Y, et al. *J Neurol* 2025;272:489; 7. Uzawa A, et al. *J Neuroimmunol* 2021;358:577634; 8. Drouin SM, et al. *J Immunol* 2001;166:2025–32; 2015;2:e119

Classical pathway / aC1s inhibition has the potential to change the CIDP landscape

| | FcRn | Complement Inhibitors | | |
|---|---|--|---|--|
| | Efgartigimod S.C. QW | Empasiprubarb (C2) I.V. Q4W | Riliprubarb (aC1s) 600mg/4mL S.C. QW | Claseprubarb (aC1s) 300mg/2mL S.C. Q2W |
| Ph. 3 Study Populations |  adhere SoC-Treated Off Treatment |  emnergize SoC-Treated Off Treatment |  Mobilize Clinical Trial SoC Refractory |  CAPTIVATE SoC-Treated SoC-Refractory SoC-Naïve |
| | |  envigorate H2H vs IVIG Treated |  Vitalize Clinical Trial H2H vs IVIG Treated | |
| Ig Withdrawal Required Prior to Entering Study ¹ | YES | NO | NO | NO |
| Study Endpoints / Results | <ul style="list-style-type: none"> Confirmed ECI² Ph. 3 Stage A results: <ul style="list-style-type: none"> – 66.5% ECI (wk 12) <p>~1/3 pts did not return to pre-Ig washout baseline</p> | <ul style="list-style-type: none"> ≥1-point aINCAT improvement | <ul style="list-style-type: none"> ≥1-point aINCAT improvement Ph. 2 PoC response rates: <ul style="list-style-type: none"> – SOC-Treated: 52% – SOC-Refractory: 50% | <ul style="list-style-type: none"> Switching Ig patients to claseprubarb 7 days after last dose Aiming for ≥1-point aINCAT improvement OVER SoC/Ig in ≥50% of patients in Part A |



aC1s inhibitors enroll a broad patient population including SOC-refractory patients



FcRns are not being evaluated H2H vs. IVIG



No requirement for disease worsening in ongoing complement trials



≥1-point aINCAT improvement used as efficacy measure in ongoing studies

Source: Company filings, presentations and clinicaltrials.gov

Ig refers to IVIG and SCIG

1. ADHERE required discontinuation of IVIG or SCIG and evidence of clinically meaningful deterioration before dosing in Part A

2. Defined as a clinical improvement on the parameters that the participant worsened in during run-in (≥4-point increase in I-RODS and/or ≥8-kPa increase in mean grip strength) or clinical improvement (≥1-point decrease) in INCAT

Accomplished team of biotech industry veterans and scientists committed to bringing innovation to market

SENIOR MANAGEMENT



Marino Garcia
President & CEO



Simrat Randhawa, M.D.
EVP, Head of R&D



Ryan Savitz
EVP, Chief Financial Officer & Chief Business Officer



John C. King
Chief Commercial Officer



Kristina Maximenko
Chief People Officer



Adam Veness, Esq.
General Counsel



Ronny Hashmonay, M.D.
Chief Development & Medical Affairs Officer



Rivka Gluck
Head of Clinical Development Operations



Sue Evans
Head of Regulatory Affairs



Edward Carr
Chief Accounting Officer



Jud Taylor
Head of Technical Operations



Jennifer Cross
VP, Pipeline Strategy & Research



Polly Hanff
Head of Quality



Scott Nogi
Head of Business Operations



Jennifer Davis Ruff
Head of Investor Relations & Corporate Affairs

Select Experience Includes:

BOARD OF DIRECTORS

Alison Lawton
Chair of the Board
Board Member, ProQR and X4,
Prior Chair of Board, Magenta

Sujay Kango
Board Member, Adanate, Inc.

Anne McGeorge
Board Member, The Oncology Institute,
Board Member, Be the Match

Simon Read, Ph.D.
Former CEO and Founder, Mariana
Oncology, Venture Partner, Atlas
Venture, Former CSO, Ra Pharma

Steven Romano, M.D.
EVP, Chief Research & Development
Officer, Silence Therapeutics, Inc.

Paula Soteropoulos
Venture Partner, 5AM Ventures

Jonathan Violin, Ph.D.
Venture Partner, Fairmount,
Co-founder of Dianthus, Board
Member, Astria Therapeutics, and
former President/CEO of Viridian
Therapeutics

Marino Garcia
President & CEO, Dianthus



Select Autoimmune Drugs
Developed by Dianthus Team

CellCept

SOLIRIS
(eculizumab)

ULTOMIRIS
(tanezumab)

Lupkynis
(voclosporin)

ZILBRYSQ
(zilucoplan) Injection